PRIMARY STUDY

The Use of Cannabidiol in Treating Psychiatric Disorders: A Systematic Review

Key Findings:  This systematic review of clinical trials on cannabidiol (CBD) for psychiatric disorders found that while CBD has a good safety profile, the evidence regarding its effectiveness in reducing symptom severity, particularly in schizophrenia, substance use disorder, and social anxiety, remains inconclusive.